# Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

> **NCT02290431** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Relapse/Refractory Multiple Myeloma

## Interventions

- **DRUG:** LBH589 (panobinostat)
- **DRUG:** bortezomib
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT02290431
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-16
- **Primary completion:** 2017-12-29
- **Final completion:** 2018-12-25
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02290431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02290431, "Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02290431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*